Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

AveXis managed to grab the industry’s attention when researchers posted early and stunning results for their life-saving gene therapy to treat rare cases of spinal muscular atrophy. They were back in the spotlight when Novartis reached out to buy the company for $8.7 billion.